Back

Latest Forum Topics / QT Vascular

Post Reply

Sing Holdings - Grossly undervalued Post Reply Rate topic
dragonn Veteran	22-May-2014 12:01        dragonn About Contact  Quote this Post!
x 0   x 0  Alert Admin	Yeah I understand that with an estimated of about 341,671 PAD patients in Singapore alot,  in year 2004 for diabetes alone, it should be more right now  for 2014.       According to a nationwide cross-sectional study in Singapore in 2004, the prevalence of diabetes among adults causing PAD aged 18 to 69 years was 8.2%. http://www.annals.edu.sg/pdf/39VolNo7Jul2010/V39N7p525.pdf   2004 4,166.7 3,413.3 753.4 (http://www.singstat.gov.sg/Publications/publications_and_papers/population_and_population_structure/respop.pdf) 4,166,730 x 8.2% = 341,671 PAD patients         *UOB-KH Initiate coverage with a BUY target price of S$0.51 represents 36% upside Does this means that UOB-KH will buy at $0.51 in 2015? How is UOB-KH playing a part here? I only know how this buisness work and the number of people around seeking this treatment per year but I dont understand how other companies play a part.   cleverboy      ( Date: 21-May-2014 22:08) Posted: Hi Dragon, In simple words, what it says is QTV has products to treat illnesses pertaining to eldery people.  The growth in the ageing population in USA, Europe, China and Japan will drive the demnad for QTV' s products (markets).  Its strategic partnership with Johnson & Johnson, Weigao and Itochu allows QTV to have fast access to distribution channels to reach end user markets, enabling its sales to grow rapidly (for eg in USA, QTV would be able to reach 1500 hospital accounts ie 10x its current reach).  The drug coated Chocolate PTA would be a paragidm-changing innovation (technology and product pipeline).   UOBKH' s target price of S$0.51 is based on 10x FY2015 price-to-sales, having made reference to past M& A deals and distribution agreements, which provide topline visibility as they set out minimum volume or projected sales target commitments to be fulfilled by the distributors.    QTV is expected to report gross profits when its sales achieves scale this year.  CR Bard, a competitor, expects the market size of drug coated ballon catheter to be US$100mil in sales in the first fully year alone after it DCB gets FDA approval. Also just to add, Singapore market is a relatively small market for QTV' s products, simply due to the small population base.  Thus the biggest market for QTV is in USA, Europe, China and Japan.  As QTV has patents over its products, any one infringing its intellectual property rights will likely be sued by the company, and you know in USA the compensation as a result of infringement of intellectual property rights is hefty.    For new entrant to compete with QTV, this competitor must first have lots of $.  The QTV prospectus shows that at least S$96 mil have been invested into the company BEFORE IPO.  Thus the barrier of entry is high.
Useful To Me  Not Useful To Me
cleverboy Member	21-May-2014 22:08        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hi Dragon, In simple words, what it says is QTV has products to treat illnesses pertaining to eldery people.  The growth in the ageing population in USA, Europe, China and Japan will drive the demnad for QTV' s products (markets).  Its strategic partnership with Johnson & Johnson, Weigao and Itochu allows QTV to have fast access to distribution channels to reach end user markets, enabling its sales to grow rapidly (for eg in USA, QTV would be able to reach 1500 hospital accounts ie 10x its current reach).  The drug coated Chocolate PTA would be a paragidm-changing innovation (technology and product pipeline).   UOBKH' s target price of S$0.51 is based on 10x FY2015 price-to-sales, having made reference to past M& A deals and distribution agreements, which provide topline visibility as they set out minimum volume or projected sales target commitments to be fulfilled by the distributors.    QTV is expected to report gross profits when its sales achieves scale this year.  CR Bard, a competitor, expects the market size of drug coated ballon catheter to be US$100mil in sales in the first fully year alone after it DCB gets FDA approval. Also just to add, Singapore market is a relatively small market for QTV' s products, simply due to the small population base.  Thus the biggest market for QTV is in USA, Europe, China and Japan.  As QTV has patents over its products, any one infringing its intellectual property rights will likely be sued by the company, and you know in USA the compensation as a result of infringement of intellectual property rights is hefty.    For new entrant to compete with QTV, this competitor must first have lots of $.  The QTV prospectus shows that at least S$96 mil have been invested into the company BEFORE IPO.  Thus the barrier of entry is high.
Useful To Me  Not Useful To Me
sunview Veteran	21-May-2014 16:44        sunview About Contact  Quote this Post!
x 0   x 0  Alert Admin	Dragonn, this could be a future dragon. I have put it in my watch list and will  closely monitor its development when the hype is over and the overall market condition improves.
Useful To Me  Not Useful To Me
dragonn Veteran	21-May-2014 16:33        dragonn About Contact  Quote this Post!
x 0   x 0  Alert Admin	Sunview, I was thinking For research interventions, 1) Funding is a great issue, to be able to get that amount of fundings for something like that is hard. 2) Patentship of the company for this ballooning technology, this company is safe for another 7 years if Singapore government practice this patentship, if any other company that comes in against  QTV can  be fined for breaching this, and ultimately most of the money that is taken from the fine will be awarded to QTV. --> I think this is the greatest company asset for QTV.   Let me know if I' m wrong in anyways. sunview      ( Date: 21-May-2014 16:24) Posted: QT Vascular (QTV) is engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally-invasive treatment of complex vascular diseases. Its product portfolio includes two coronary devices and three peripheral devices, one of which is its flagship Chocolate® PTA Balloon Catheter (Chocolate PTA). It carries out its operations from two locations &ndash Pleasanton, California and Singapore &ndash and has a distribution presence in the US, Europe, Japan and China. It is a start-up company which is still not making money yet. If you want to buy based on the balance sheet, you will not be buying it. People invest in a start-up for its potential in the future, which may not be fulfilled. It is beauty in the eye of the beholder. At the moment, it is trading at new high of $0.405. I have sold mine already  in view of the overall poor market sentiment.
Useful To Me  Not Useful To Me
kc0257 Member	21-May-2014 16:26        kc0257 About Contact  Quote this Post! Style: Flexible   Mood:
x 0   x 0  Alert Admin	It is really going quite big. People keep buying since 4:01:11. Looks like more BB are in.
Useful To Me  Not Useful To Me
dragonn Veteran	21-May-2014 16:24        dragonn About Contact  Quote this Post!
x 0   x 0  Alert Admin	Seems quite legit, somethings not right in this last hour. With a sudden increase of trade of like 2k lots with only 12k done the whole day. 2k lots is about SGD$800,000 done in the past 30mins who is the guy that is doing all these trades? Anyone with any clue?     A total of 5 million SGD was traded
Useful To Me  Not Useful To Me
sunview Veteran	21-May-2014 16:24        sunview About Contact  Quote this Post!
x 0   x 0  Alert Admin	QT Vascular (QTV) is engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally-invasive treatment of complex vascular diseases. Its product portfolio includes two coronary devices and three peripheral devices, one of which is its flagship Chocolate® PTA Balloon Catheter (Chocolate PTA). It carries out its operations from two locations &ndash Pleasanton, California and Singapore &ndash and has a distribution presence in the US, Europe, Japan and China. It is a start-up company which is still not making money yet. If you want to buy based on the balance sheet, you will not be buying it. People invest in a start-up for its potential in the future, which may not be fulfilled. It is beauty in the eye of the beholder. At the moment, it is trading at new high of $0.405. I have sold mine already  in view of the overall poor market sentiment.
Useful To Me  Not Useful To Me
ytoh1688 Veteran	21-May-2014 16:16        ytoh1688 About Contact  Quote this Post!
x 0   x 0  Alert Admin	if don' t trust uobkh...may be can look at the cornerstone investors...most of them are in the industry themselves
Useful To Me  Not Useful To Me
kc0257 Member	21-May-2014 16:05        kc0257 About Contact  Quote this Post! Style: Flexible   Mood:
x 0   x 0  Alert Admin	Coming on quite fierce. 16:04:52 0.405 1,000 Buy Up 16:04:52 0.405 29,000 Buy Up 16:03:54 0.405 3,000 Buy Up 16:03:32 0.405 5,000 Buy Up 16:03:31 0.405 2,000 Buy Up 16:03:23 0.405 3,000 Buy Up 16:03:22 0.405 20,000 Buy Up 16:03:21 0.405 1,000 Buy Up 16:03:21 0.405 1,000 Buy Up 16:03:15 0.405 100,000 Buy Up 16:03:11 0.405 36,000 Buy Up 16:03:11 0.405 64,000 Buy Up 16:03:10 0.405 10,000 Buy Up 16:01:38 0.405 5,000 Buy Up 16:01:36 0.405 5,000 Buy Up 16:01:26 0.405 5,000 Buy Up 16:01:23 0.405 3,000 Buy Up 16:01:19 0.405 2,000 Buy Up 16:01:15 0.405 3,000 Buy Up 16:01:11 0.405 2,000 Buy Up 15:58:53 0.400 4,000 Sell Down 15:58:26 0.400 1,000 Sell Down 15:56:35 0.405 1,000 Buy Up 15:56:09 0.400 50,000 Sell Down 15:53:27 0.400 1,000 Sell Down 15:53:03 0.400 64,000 Sell Down 15:53:03 0.400 5,000 Sell Down 15:53:03 0.400 300,000 Sell Down 15:53:03 0.400 20,000 Sell Down 15:53:03 0.400 10,000 Sell Down 15:53:03 0.400 1,000 Sell D
Useful To Me  Not Useful To Me
dragonn Veteran	21-May-2014 15:56        dragonn About Contact  Quote this Post!
x 0   x 0  Alert Admin	Sorry I dont understand what is the juice of this. Can summarise this text i' ve quoted? Also where you got the information. You' ve an account to this?http://research.uobkayhian.com/ sunview      ( Date: 20-May-2014 16:04) Posted: *UOB-KH Initiate coverage with a BUY target price of S$0.51 represents 36% upside. Our target price was derived using a 2015F P/S ratio of 10x, which is based on completed comparable medical device M& A deals beginning 2012. The multiple is at the high end of the range, justified by QTV&rsquo revenue-generating product portfolio, strong distribution partnerships and potentially paradigm-changing device in the Drug-coated Chocolate PTA (DCC). We also note that a loss-making US medical device company, TriVascular Technologies, was listed on the NASDAQ in Apr 14 at an implied 14x 2013 P/S. At 14x, our target price for QTV would be S$0.71 but this is not our base case scenario.  *Share in the US$4.8b PV device market which is estimated to grow at a 7.1% CAGR (2011-18) to US$7.8b. The US and Europe, which hold US$3.8b of the peripheral vascular (PV) device market, are expected to grow at a 5% CAGR through to 2017. The whole of Asia is expected to grow at an 8% CAGR.  *Niche healthcare play on a growing ageing population. The combined over-65- year-old population in the US, Europe, China and Japan is expected to reach 400m by 2020, an addition of 100m from 2010. The steady growth in the over-65-year-old population will drive demand for QTV&rsquo PV devices, which are used to treat diseases that are most prevalent in this age group.  *Strategic partnerships to fast-track expansion of global distribution reach... Agreements with distributors Century Medical (CMI) for Japan, Weihai Weigao Medical Devices (Weigao) for China and Cordis Corporation (J& J) for the US and the rest of the world give QTV immediate access to potential end-user accounts. In the US, this grows the group&rsquo contact network by at least 10x to over 1,500 hospital accounts.  *&hellip nd drive our projected 176% 3-year sales CAGR. The agreements provide topline visibility as they set out minimum volume or projected sales target commitments to be fulfilled by the distributors. We expect the group to begin recognising gross profits in 2014 as it achieves scale.  * Paradigm-changing device with flagship Chocolate technology is in the pipeline through a drug-coated balloon catheter (DCB). The device is the newest PV innovation that is highly-anticipated for a debut in the US. QTV is one of the few players in the race to release the first approved device of its kind in the US. The potential for improved patient outcomes will allow for a higher selling price and market share gains. As an indication of a DCB&rsquo market potential, C.R. Bard anticipates US$100m in sales in the first full year after its DCB receives FDA approval.  Key risks include regulatory, developmental, product liability and price risks.
Useful To Me  Not Useful To Me
cleverboy Member	21-May-2014 10:48        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Conventional valuation methods may not be that suitable for Bio-tech stocks, internet stocks and pharmaceutical stocks that are at the early phase of their product/business cycle.    It is also not suitable for  oil and gas exploration company, minerals mines that have done enough exploration to prove the existence of mineral resources but yet only half way to actual production.    So valuation method does have to be adjusted to fit the situation.  Else any business that does not make money or loss making would have negative value? Also to point out is that conventional valuation method may not be appropriate in an M& A situation.  For example, AstraZeneca is trading at trailing 44x PE Ratio and forward PER of 17.4x  and the current market cap is US$91 bil.  Pfizer is proposing to buy AstraZeneca for US$117 bil.  Is this valuation in the conventional view make sense?
Useful To Me  Not Useful To Me
tea444u Elite	20-May-2014 17:37        tea444u About Contact  Quote this Post!   Mood:
x 0   x 0  Alert Admin	loss making..pure gamble now. sunview      ( Date: 20-May-2014 16:04) Posted: *UOB-KH Initiate coverage with a BUY target price of S$0.51 represents 36% upside. Our target price was derived using a 2015F P/S ratio of 10x, which is based on completed comparable medical device M& A deals beginning 2012. The multiple is at the high end of the range, justified by QTV&rsquo revenue-generating product portfolio, strong distribution partnerships and potentially paradigm-changing device in the Drug-coated Chocolate PTA (DCC). We also note that a loss-making US medical device company, TriVascular Technologies, was listed on the NASDAQ in Apr 14 at an implied 14x 2013 P/S. At 14x, our target price for QTV would be S$0.71 but this is not our base case scenario.  *Share in the US$4.8b PV device market which is estimated to grow at a 7.1% CAGR (2011-18) to US$7.8b. The US and Europe, which hold US$3.8b of the peripheral vascular (PV) device market, are expected to grow at a 5% CAGR through to 2017. The whole of Asia is expected to grow at an 8% CAGR.  *Niche healthcare play on a growing ageing population. The combined over-65- year-old population in the US, Europe, China and Japan is expected to reach 400m by 2020, an addition of 100m from 2010. The steady growth in the over-65-year-old population will drive demand for QTV&rsquo PV devices, which are used to treat diseases that are most prevalent in this age group.  *Strategic partnerships to fast-track expansion of global distribution reach... Agreements with distributors Century Medical (CMI) for Japan, Weihai Weigao Medical Devices (Weigao) for China and Cordis Corporation (J& J) for the US and the rest of the world give QTV immediate access to potential end-user accounts. In the US, this grows the group&rsquo contact network by at least 10x to over 1,500 hospital accounts.  *&hellip nd drive our projected 176% 3-year sales CAGR. The agreements provide topline visibility as they set out minimum volume or projected sales target commitments to be fulfilled by the distributors. We expect the group to begin recognising gross profits in 2014 as it achieves scale.  * Paradigm-changing device with flagship Chocolate technology is in the pipeline through a drug-coated balloon catheter (DCB). The device is the newest PV innovation that is highly-anticipated for a debut in the US. QTV is one of the few players in the race to release the first approved device of its kind in the US. The potential for improved patient outcomes will allow for a higher selling price and market share gains. As an indication of a DCB&rsquo market potential, C.R. Bard anticipates US$100m in sales in the first full year after its DCB receives FDA approval.  Key risks include regulatory, developmental, product liability and price risks.
Useful To Me  Not Useful To Me
sheerluck Supreme	20-May-2014 16:41        sheerluck About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Work for your money first then let your money work for you"
x 0   x 0  Alert Admin	UOB HayHian is the  Placement Agent. I am amazed at the variety of ways analysts comes up with to justify the valuation of a company.     If a company is loss-making they use P/S.    It will be much more solid if it can sustain it with solid bottomline. All the original investors and the pre-IPO investors are now laughing to the bank.    I hope you are also laughing with them.   Anyway, ride along the wave but keep the six-month lock-in in your calender!   Happy huating! DYDD.
Useful To Me  Not Useful To Me
sunview Veteran	20-May-2014 16:04        sunview About Contact  Quote this Post!
x 0   x 0  Alert Admin	*UOB-KH Initiate coverage with a BUY target price of S$0.51 represents 36% upside. Our target price was derived using a 2015F P/S ratio of 10x, which is based on completed comparable medical device M& A deals beginning 2012. The multiple is at the high end of the range, justified by QTV&rsquo revenue-generating product portfolio, strong distribution partnerships and potentially paradigm-changing device in the Drug-coated Chocolate PTA (DCC). We also note that a loss-making US medical device company, TriVascular Technologies, was listed on the NASDAQ in Apr 14 at an implied 14x 2013 P/S. At 14x, our target price for QTV would be S$0.71 but this is not our base case scenario.  *Share in the US$4.8b PV device market which is estimated to grow at a 7.1% CAGR (2011-18) to US$7.8b. The US and Europe, which hold US$3.8b of the peripheral vascular (PV) device market, are expected to grow at a 5% CAGR through to 2017. The whole of Asia is expected to grow at an 8% CAGR.  *Niche healthcare play on a growing ageing population. The combined over-65- year-old population in the US, Europe, China and Japan is expected to reach 400m by 2020, an addition of 100m from 2010. The steady growth in the over-65-year-old population will drive demand for QTV&rsquo PV devices, which are used to treat diseases that are most prevalent in this age group.  *Strategic partnerships to fast-track expansion of global distribution reach... Agreements with distributors Century Medical (CMI) for Japan, Weihai Weigao Medical Devices (Weigao) for China and Cordis Corporation (J& J) for the US and the rest of the world give QTV immediate access to potential end-user accounts. In the US, this grows the group&rsquo contact network by at least 10x to over 1,500 hospital accounts.  *&hellip nd drive our projected 176% 3-year sales CAGR. The agreements provide topline visibility as they set out minimum volume or projected sales target commitments to be fulfilled by the distributors. We expect the group to begin recognising gross profits in 2014 as it achieves scale.  * Paradigm-changing device with flagship Chocolate technology is in the pipeline through a drug-coated balloon catheter (DCB). The device is the newest PV innovation that is highly-anticipated for a debut in the US. QTV is one of the few players in the race to release the first approved device of its kind in the US. The potential for improved patient outcomes will allow for a higher selling price and market share gains. As an indication of a DCB&rsquo market potential, C.R. Bard anticipates US$100m in sales in the first full year after its DCB receives FDA approval.  Key risks include regulatory, developmental, product liability and price risks.
Useful To Me  Not Useful To Me
Acl2013 Veteran	20-May-2014 15:40        Acl2013 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Bro francisd, kindly copy the report and paste here? francisd      ( Date: 20-May-2014 13:27) Posted: TODAY UOBKayhian said to buy with a TP of .51 cents. Cheers.
Useful To Me  Not Useful To Me
francisd Master	20-May-2014 13:27        francisd About Contact  Quote this Post! Style: Combined   Mood: Yells: "BUY LOW SELL HIGH"
x 0   x 0  Alert Admin	TODAY UOBKayhian said to buy with a TP of .51 cents. Cheers.
Useful To Me  Not Useful To Me
dragonn Veteran	20-May-2014 12:56        dragonn About Contact  Quote this Post!
x 0   x 0  Alert Admin	Anyway don' t know this will be helpful to you guys NOTICE OF ANNUAL GENERAL MEETING 28th May 2014 http://infopub.sgx.com/Apps?A=COW_CorpAnnouncement_Content& B=AnnouncementLast3Months& F=HJ44GIEKJQ0LC63B& fileId=Notice_of_AGM.pdf 　 Anyone with insider news to share? You will be blessed by everyone.
Useful To Me  Not Useful To Me
think2profit Master	17-May-2014 11:15        think2profit About Contact  Quote this Post!
x 0   x 0  Alert Admin	Looking thru the AR, you could see many UHNW in the top 20 shareholders list: Tommie Goh Jeremy Lee Steven Lim Lim Chye Huat
Useful To Me  Not Useful To Me
Markie Senior	16-May-2014 21:21        Markie About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hold this for long term and u will see how big it becomes. Raffles medical used to be less than 50 cents in the past also Breeze      ( Date: 13-May-2014 17:05) Posted: Est. 40-42 target price. gd luck
Useful To Me  Not Useful To Me
dragonn Veteran	16-May-2014 20:41        dragonn About Contact  Quote this Post!
x 0   x 0  Alert Admin	I quite agree QT vascular can go quite big to very very big   QT Vascular " We are delighted to see TriReme gain this level of global recognition," stated Mr. Michael Kleine, board member of QT Vascular and former CEO of Biosensors International. " TriReme management has been building a valuable business by driving strong market adoption for its products backed with excellent clinical data." (https://sg.finance.yahoo.com/news/biosensors-international-group-ltd-management-080000320.html)   CLINICAL RESEARCH IN PERIPHERAL ARTERIAL DISEASE http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-03-003.html PAD treatment options http://www.singhealth.com.sg/PatientCare/ConditionsAndTreatments/Pages/Peripheral-Arterial-Disease.aspx   According to a nationwide cross-sectional study in Singapore in 2004, the prevalence of diabetes among adults aged 18 to 69 years was 8.2%. http://www.annals.edu.sg/pdf/39VolNo7Jul2010/V39N7p525.pdf   2004 4,166.7 3,413.3 753.4 (http://www.singstat.gov.sg/Publications/publications_and_papers/population_and_population_structure/respop.pdf) 4,166,730 x 8.2% = 341,671 PAD patients   Pravalence of PAD with amputation The prevalence of PAD, defi ned as resting ABI of < 0.9 on either leg and/or a history of gangrene or non-traumatic amputation was 15.2% [95% confi - dence interval (CI), 12.3-18.5]. http://www.annals.edu.sg/pdf/39VolNo7Jul2010/V39N7p525.pdf (based on 521 patients) Approached 697 patients from 3607 patients (Diabetes Patients) Study population consisted of 67.0% Chinese, 15.2% Malays, 16.1% Indians and 1.7% of other ethnic groups. The prevalence of PAD among the patients with diabetes in our study was 15.2%, 341,671 x (12.3% - 18.5%) = 42025 &ndash 63209 patients Confidence level =  51933 patients average   Imagine every year on average that much patients coming up with that disease especially with aging population. It' s a potential buisness. And in research, its hard to get funding for such a buisness and it takes years to create another product as reliable as this. As mentioned in QT vascular, one of the potential risk factor is manufacturing defect that could cause confidence lost to the public. This defects happens everywhere including vehicles, as long as machines is involved, defects could hardly be inevitable, and of course this defects problem could be avoided with strong Quality control. I doubt it' ll create any strong impact  as there' s not much choices around and everyone will definately need to save their own limbs at that point of time. Also I believe majority of the people can claim their medisave and insurance for such a problem if it occurs.   This is purely my own opinion for this buisness, correct me if I' m wrong
Useful To Me  Not Useful To Me

                                                         First   < Newer   1241-1260 of 1629   Older>   Last